The rare disease clinical trial landscape
There are over 7,000 rare diseases affecting 300 million people worldwide, yet the majority have no approved treatment. The rare disease clinical trial space has exploded in recent years, driven by gene therapy advances, FDA orphan drug incentives, and growing investment from both large pharma and specialist biotechs.
For rare disease professionals, staying current with the trial landscape is critical and uniquely difficult. Conditions are highly specific, trials are small, and the difference between a recruiting trial and a completed one matters enormously to patients who may have exhausted other options.
Track your rare disease area automatically
Set your condition keywords once. Get new and updated trials every morning.
Start FreeUse cases for rare disease trial monitoring
Patient advocacy organizations
Disease foundations and patient groups play a critical role in connecting patients to clinical trial opportunities. When a new recruiting trial opens for Duchenne muscular dystrophy, Pompe disease, or a rare metabolic disorder, advocacy organizations need to know immediately so they can alert their communities.
Rare disease biotech companies
Companies developing orphan drugs need to know when competitors register new programs in their target indication. A new Phase 2 gene therapy for the same condition changes the competitive landscape and may affect licensing strategy, partnership discussions, and investor messaging.
Academic medical center specialists
Rare disease specialists at academic centers refer patients to clinical trials. Knowing what's currently recruiting — and when status changes — directly affects patient care decisions.
Example rare disease profiles to track
- Spinal muscular atrophy (SMA) — gene therapy and antisense oligonucleotide programs
- Duchenne muscular dystrophy (DMD) — exon-skipping and micro-dystrophin programs
- Cystic fibrosis — CFTR modulator combinations beyond approved therapies
- Sickle cell disease and beta thalassemia — gene editing and gene therapy
- Lysosomal storage disorders — enzyme replacement and substrate reduction therapies
- Rare neurological conditions — CLN disease, Rett syndrome, Angelman syndrome
Track rare disease trials
free plan — no credit card required. Your search profile, your filters.
Start Free60 active trials, 44 recruiting.
Industry sponsors run 4 of these trials. The rest are run by universities, hospitals, government bodies and other non-commercial sponsors. The table below lists all 4 of them.
| Top industry sponsor | Active trials |
|---|---|
| AstraZeneca | 1 |
| Munich Leukemia Laboratory | 1 |
| Napo Pharmaceuticals, Inc. | 1 |
| Sanguine Biosciences | 1 |
| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| Longitudinal Studies of Patient With FPDMM NCT03854318 | Recruiting | Completion pushed: 2028-12-31 → 2099-12-31 | 2026-09-12 |
| ScATtEred Rare Disease Biobanks: a Model of Sample/Data Collection With… NCT06782230 | Recruiting | Completion pushed: 2026-08-30 → 2027-03-01 | 2026-08-28 |
| Education & Care in RARE: Efficacy of Targeted Psychoeducational Intervention… NCT06729554 | Recruiting | Completion pushed: 2027-12-01 → 2028-12-01 | 2026-07-29 |
| AI-assisted Rare Disease Diagnosis NCT07650799 | Not Yet Recruiting | Primary endpoint(s) modified | 2026-07-28 |
| Genetic Analysis of Uncommon Disease Presentations in Non-US Populations NCT06595940 | Recruiting | None in the last 90 days |
Each trial page shows every change DataLookout has recorded for that trial.
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top trial). No credit card.
Starter, $49/month: 3 sponsor + 3 disease watchlists, 3 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list and landscape reports.
Pro, $149/month: unlimited sponsor and disease watchlists, unlimited saved searches, track unlimited individual trials, CSV export, priority email support.